California Public Employees Retirement System Has $47.36 Million Stock Position in Exelixis, Inc. (NASDAQ:EXEL)

California Public Employees Retirement System boosted its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 11.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,974,291 shares of the biotechnology company’s stock after buying an additional 203,163 shares during the quarter. California Public Employees Retirement System’s holdings in Exelixis were worth $47,363,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of EXEL. American Century Companies Inc. lifted its position in Exelixis by 31.5% during the third quarter. American Century Companies Inc. now owns 1,410,113 shares of the biotechnology company’s stock worth $30,811,000 after acquiring an additional 338,021 shares during the last quarter. State of Alaska Department of Revenue grew its holdings in Exelixis by 236.3% in the 4th quarter. State of Alaska Department of Revenue now owns 127,287 shares of the biotechnology company’s stock valued at $3,053,000 after buying an additional 89,436 shares in the last quarter. Exchange Traded Concepts LLC increased its position in Exelixis by 244.5% during the 4th quarter. Exchange Traded Concepts LLC now owns 118,359 shares of the biotechnology company’s stock worth $2,839,000 after buying an additional 83,999 shares during the period. Advisors Preferred LLC acquired a new stake in shares of Exelixis during the fourth quarter worth $3,384,000. Finally, Seven Eight Capital LP boosted its position in shares of Exelixis by 61.7% in the third quarter. Seven Eight Capital LP now owns 21,765 shares of the biotechnology company’s stock valued at $476,000 after acquiring an additional 8,305 shares during the period. Institutional investors own 85.27% of the company’s stock.

Insider Buying and Selling at Exelixis

In other Exelixis news, Director David Edward Johnson purchased 190,000 shares of the business’s stock in a transaction dated Wednesday, February 21st. The shares were bought at an average price of $20.70 per share, for a total transaction of $3,933,000.00. Following the completion of the acquisition, the director now owns 1,100,730 shares in the company, valued at $22,785,111. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director David Edward Johnson acquired 190,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 21st. The shares were bought at an average cost of $20.70 per share, with a total value of $3,933,000.00. Following the completion of the purchase, the director now directly owns 1,100,730 shares in the company, valued at $22,785,111. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Patrick J. Haley sold 47,020 shares of the company’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $21.45, for a total value of $1,008,579.00. Following the completion of the sale, the executive vice president now owns 384,866 shares in the company, valued at $8,255,375.70. The disclosure for this sale can be found here. Corporate insiders own 2.90% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. William Blair reaffirmed an “outperform” rating on shares of Exelixis in a research report on Friday, January 26th. Royal Bank of Canada upped their target price on Exelixis from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. JMP Securities restated a “market outperform” rating and issued a $27.00 price target on shares of Exelixis in a research report on Wednesday, April 10th. TheStreet raised shares of Exelixis from a “c+” rating to a “b-” rating in a research report on Monday, March 18th. Finally, Barclays downgraded shares of Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 price objective on the stock. in a research note on Thursday, April 11th. Six equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $26.29.

Exelixis Stock Up 0.7 %

Shares of EXEL opened at $23.70 on Friday. The stock has a market cap of $6.99 billion, a PE ratio of 37.03, a PEG ratio of 0.63 and a beta of 0.54. Exelixis, Inc. has a 12-month low of $18.08 and a 12-month high of $24.34. The business has a 50-day simple moving average of $22.80 and a two-hundred day simple moving average of $22.18.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, February 6th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.02. The company had revenue of $479.65 million during the quarter, compared to the consensus estimate of $481.23 million. Exelixis had a return on equity of 8.57% and a net margin of 11.35%. On average, equities research analysts expect that Exelixis, Inc. will post 1.21 EPS for the current year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.